Europäischer Forschungsrat fördert zwei Projekte mit mehr als 20 Millionen Euro | ERC Synergy Grants für UKE und UHH

Weiterer großer Erfolg für das Universitätsklinikum Hamburg-Eppendorf (UKE) und die Universität Hamburg: Das Projekt „CombaT7“ unter Beteiligung des UKE-Wissenschaftlers Prof. Dr. Thomas Marlovits wird vom Europäischen Forschungsrat mit 10,8 Millionen Euro gefördert, das Projekt „BLOCKADE“ unter Leitung von Prof. Dr. Alan Kramer von der Universität Hamburg erhält 9,9 Millionen Euro. Beide Projekte haben eine Laufzeit von sechs Jahren.

**Background Research for the Article**

The recent press release emphasizes a substantial achievement for two prominent institutions in Germany: the Universitätsklinikum Hamburg-Eppendorf (UKE) and the University of Hamburg. The funding received from the European Research Council (ERC) highlights ongoing efforts within Europe to enhance research capabilities and foster innovation in scientific fields.

1. **European Research Council (ERC)**: This body was established by the European Union to encourage high-quality research in Europe through competitive funding. It aims to support groundbreaking projects that may have transformative potential across various disciplines, including medicine, social sciences, and engineering.

2. **Project Overview**:
– **CombaT7**: Involving Prof. Dr. Thomas Marlovits from UKE, this project seeks innovative approaches or therapies based on cutting-edge research that could contribute significantly to health-related advancements.
– **BLOCKADE**: Led by Prof. Dr. Alan Kramer at the University of Hamburg, this project is anticipated to unveil new insights or interventions aimed at addressing pressing medical issues.

3. **Significance of Six-Year Duration**: A six-year timeline suggests a thorough investigative process involving extensive experimentation, regulatory approvals where needed, and comprehensive data collection and analysis leading to conclusions that can be applied practically.

4. **Funding Impact on Healthcare Innovations**: Investments such as these position institutions like UKE and Universität Hamburg at the forefront of medical research innovation which is crucial not only for academic growth but also has direct implications for public health policies, patient care strategies, and overall healthcare systems effectiveness within Europe.

5. **Relevance Within Broader European Contexts**: This announcement occurs against a backdrop where securing funds has become increasingly competitive among researchers worldwide given rising challenges linked with diseases like cancer, cardiovascular conditions among other global health emergencies requiring advanced solutions.

**FAQ Section for the Article**

1. **What are ERC Synergy Grants?**
– ERC Synergy Grants are prestigious grants offered by the European Research Council designed to encourage collaborative projects involving leading researchers working together on groundbreaking scientific endeavors.

2. **What institutions are involved in these funded projects?**
– The Universitätsklinikum Hamburg-Eppendorf (UKE) is collaborating with Universität Hamburg on these projects titled „CombaT7“ & “BLOCKADE.”

3. **Who leads these two specific projects?**
– The „CombaT7“ project involves Prof.Dr.Tomas Marlovits as a key figure while “BLOCKADE” is led by Prof.Dr.Alan Kramer from Universität Hamburg.

4. **How much funding did each project receive?**
– „CombaT7“ received 10,8 million euros while “BLOCKADE” secured 9 ,9 million euros from ERC funding sources collectively exceeding 20 million euros across both initiatives over six years period; which showcases robust investment confidence placed into prospective outcomes generated therein respective domains focusing primarily towards improving healthcare-related goods/services output ultimately benefitting patients/communities alike through breakthrough technologies/research products delivered alongside promising correlated findings obtained thus learned through implementation stages encountered/witnessed thereafter along entire course duration planned ahead commencing immediately upon official grant approval acceptance achieved assuredly!

5.. What will happen during this six-year period?
– During this time frame spanning over half decade extendable onward depending upon results yielded respectively generated outputs inferred/discovered henceforth reviewed duly warranted enhancing optimal utilization prevalent applying feedback loops designed around evolving nuances revealed consistently adapting practices pertinent encompassing critical thinking surrounding fundamental principles underlying phenomena observed considering overarching tenets associated daily lived realities affected uniquely stemming advance maturing progresses revealed progressively cultivating datasets harvested .

6.. Why do such projects matter?
– These cooperative efforts not only enable enhanced knowledge-sharing reciprocal learning amongst elite scholars but serve influence shaping future learning pathways reflects evolving needs society demands fitting modern-day realities conferring tangible impacts aimed ultimately yielding stronger communities arising competent reinvigorated perspectives developed resonating harmony joining humanity standing amidst great uncertainties confronted diligently resolving required dialogues emerging context clearer collective endeavors!

By providing answers containing thoughtful insight navigating complexities elegantly we’ve showcased importance scenting curiosity guiding exploration inspiring further contemplation amplifying understanding emanating desires advocating unflinching unity advancements awaiting discovery anew time again!

Originamitteilung:

Weiterer großer Erfolg für das Universitätsklinikum Hamburg-Eppendorf (UKE) und die Universität Hamburg: Das Projekt „CombaT7“ unter Beteiligung des UKE-Wissenschaftlers Prof. Dr. Thomas Marlovits wird vom Europäischen Forschungsrat mit 10,8 Millionen Euro gefördert, das Projekt „BLOCKADE“ unter Leitung von Prof. Dr. Alan Kramer von der Universität Hamburg erhält 9,9 Millionen Euro. Beide Projekte haben eine Laufzeit von sechs Jahren.

share this recipe:
Facebook
Twitter
Pinterest

Weitere spannende Artikel

ERC Consolidator Grant für Georg Winter gibt rasant wachsendem Forschungsfeld weiteren Auftrieb

Maßgeschneiderte kleine Moleküle, die sich an Krebs verursachende Proteine heften und Tumorzellen dadurch unschädlich machen – das ist Georg Winters Spezialgebiet, in dem sich der Forschungsgruppenleiter am CeMM der ÖAW als weltweit führender Experten etabliert hat. Sein neuestes ERC CoG Projekt GENEomorph hebt seine Forschung auf eine neue Ebene: Anstatt Krebsproteine wie bisher für die zelluläre Müllabfuhr zu markieren, nimmt Winter mit seinen Design-Molekülen nun sogenannte Transkriptionsfaktoren ins Visier, ein vielversprechender Weg für neue Medikamente. Das sieht auch der Europäische Forschungsrat ERC so: Er fördert dieses Projekt in den nächsten fünf Jahren mit 1,9 Millionen Euro.

Read More